Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer

Urol Int. 2002;68(2):122-5. doi: 10.1159/000048432.

Abstract

Thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) levels in transitional cell carcinoma of the bladder resected from 38 patients were examined by ELISA. TP levels in high-grade and invasive cancer were significantly higher than those in low-grade and superficial cancer, respectively. No significant differences in the DPD levels were observed among grades and stages, but the DPD/TP ratio was significantly lower in grade 3 tumor than in grade 1. These results demonstrated that 5'-deoxy-5-fluorouridine seemed to be useful for managing patients with grade 3 cancer. The present study also suggested that we might be able to exclude cases of bladder cancer in which 5-fluorouracil group medicines would be inappropriate candidates in treatment options by measuring both TP and DPD levels in the tumor.

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / enzymology*
  • Dihydrouracil Dehydrogenase (NADP)
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fluorouracil / therapeutic use
  • Humans
  • Male
  • Oxidoreductases / metabolism*
  • Thymidine Phosphorylase / metabolism*
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / enzymology*

Substances

  • Antineoplastic Agents
  • Oxidoreductases
  • Dihydrouracil Dehydrogenase (NADP)
  • Thymidine Phosphorylase
  • Fluorouracil